SANTA CLARA, Calif., Oct. 31 Bacchus Vascular Inc., aleading provider of innovative medical devices used by interventionalradiologists and vascular surgeons for the minimally invasive treatment ofdeep vein thrombosis (DVT) and other peripheral vascular disease, announcedtoday that it has named Dennis Rosenberg to the position of Vice President ofMarketing.
Mr. Rosenberg has over 25 years experience in medical device and consumermarketing and sales. Most recently he served as Vice President of Marketingand International Sales for VNUS Medical Technologies from 2005 until June,2007. From 1999 to 2005 he owned and operated a marketing communicationsconsultancy, Metaphor Media, and from 2002 to 2004 concurrently served asChief Marketing Officer at Acueity, Inc., a micro-endoscopy medical devicecompany. Prior to that, he was co-founder and VP of Marketing and Sales for MDDataDirect, an internet medical information company, and VP and GM ofRandomsoft, the software distribution division of Random House. He was alsoco-founder and VP, Marketing and Sales of Eclipse Surgical Technologies, amedical laser company, and co-founder and VP, Marketing and Sales of AtlantisCatheter Company, a cardiovascular device company.
"Dennis Rosenberg has a broad background in marketing, both inside andoutside the medical device field," said Scott Cramer, President and CEO ofBacchus Vascular. "He brings a wealth of relevant knowledge and experience indevice marketing and physician practice building programs to Bacchus Vascular,and we are pleased to have his leadership in our marketing efforts."
Mr. Rosenberg studied film and television production as well as computerprogramming at New York University, computer graphics at University ofCalifornia Santa Cruz and graphic design at The New School in New York.
About Bacchus Vascular
Bacchus Vascular, Inc. is a privately held medical device companydedicated to the treatment of peripheral vascular disease. Dr. Thomas Fogarty,a noted inventor and cardiovascular surgeon, founded the company with thevision of transforming blood clot removal from peripheral blood vessels into afast, simple, minimally-invasive catheter-based procedure. Thousands ofpatients suffering from DVT and other occlusive vascular diseases have beentreated worldwide to date using the company's Trellis(R) Peripheral InfusionSystem and other products.
For more information, visit http://www.bacchusvascular.com.
SOURCE Bacchus Vascular Inc.